NCT05282069View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of DA-8010 in Patients With Overactive Bladder

PHASE3CompletedINTERVENTIONAL
Enrollment

607

Participants

Timeline

Start Date

May 12, 2022

Primary Completion Date

November 1, 2023

Study Completion Date

May 29, 2024

Conditions
Overactive Bladder
Interventions
DRUG

DA-8010 Placebo

Participants receive placebo to match DA-8010 orally once a day.

DRUG

DA-8010 2.5mg

Participants receive DA-8010 2.5mg orally once a day.

DRUG

DA-8010 5mg

Participants receive DA-8010 5mg orally once a day.

DRUG

Solifenacin 5mg

Participants receive solifenacin 5 mg orally once a day.

DRUG

Solifenacin succinate placebo

Participants receive placebo to match solifenacin 5 mg orally once a day.

Trial Locations (1)

Unknown

Severance Hospital, Seoul

All Listed Sponsors
lead

Dong-A ST Co., Ltd.

INDUSTRY